Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagonist
The present invention provides methods for decreasing a nasal polyp score in a subject. The methods include administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist such as an anti-IL-4R antibody or antigen binding fragment thereof.
1. A method for treating chronic rhinosinusitis with nasal polyposis (CRSwNP) in a subject in need thereof comprising administering to the subject a pharmaceutical composition comprising an antibody or antigen binding fragment thereof that specifically binds an interleukin-4 receptor (IL-4R), wherein the antibody or antigen binding fragment thereof comprises light chain CDR sequences of SEQ ID NOs: 6, 7 and 8, and heavy chain CDR sequences of SEQ ID NOs: 3, 4 and 5.
2. The method of claim 1 , wherein one or more maintenance doses of intranasal corticosteroid (INCS) are administered to the subject.
3. The method of claim 2 , wherein the INCS is mometasone furoate nasal spray (MFNS).
4. The method of claim 3 , wherein the MFNS administered at a dose of about 100 mg to each nostril of the subject once or twice a day.
5. The method of claim 1 , wherein the subject has a total of at least 5 nasal polyps, with two or more nasal polyps present in each nostril.
6. The method of claim 1 , wherein the subject has severe chronic rhinosinusitis with bilateral nasal polyposis.
7. The method of claim 1 , wherein the subj ect has co-morbid asthma.
8. The method of claim 1 , wherein the antibody, or antigen binding fragment thereof, is administered as an add-on maintenance treatment.
9. The method of claim 1 , wherein the subject further has one or more conditions selected from the group consisting of allergic rhinitis, asthma, aspirin hypersensitivity, and non-steroidal anti-inflammatory drug (NSAID) hypersensitivity.
10. The method of claim 1 , wherein:
the subject has undergone surgery for one or both of nasal polyps and chronic rhinosinusitis;
a first functional endoscopy sinus surgery (FESS) is indicated, a revised surgery is indicated, or surgery is contraindicated; and/or
the antibody, or antigen binding fragment thereof, reduces a need for treatment with oral corticosteroids, systemic corticosteroids, and/or reduces a need for nasal polyp surgery.
11. The method of claim 1 , wherein the method:
decreases nasal polyp score (NPS) by about 10% to about 50%, by about 20% to about 40%, or by about 25% to about 30%, and/or
improves one or more of loss of smell, runny nose, post nasal drip and nasal peak inspiratory flow, in the day (AM), at night (PM) or both in the AM and in the PM.
12. The method of claim 1 , wherein the antibody, or the antigen binding fragment thereof, is administered subcutaneously.
13. The method of claim 12 , wherein the antibody, or antigen binding fragment thereof, is administered using an autoinjector, a needle and syringe, or a pen delivery device.
14. The method of claim 1 , wherein the antibody, or the antigen binding fragment thereof, is administered in one or more doses of about 300 mg.
15. The method of claim 1 , wherein the antibody, or antigen binding fragment thereof, is administered in an initial dose of about 300 mg, and in one or more subsequent doses of about 300 mg each, and wherein the subsequent doses are administered once every 14 days.
16. The method of claim 1 , wherein the antibody, or antigen binding fragment thereof, comprises an HCVR having the amino acid sequence of SEQ ID NO:1 and an LCVR having the amino acid sequence of SEQ ID NO:2.
17. The method of claim 16 , wherein the antibody is dupilumab.
18. The method of claim 1 , wherein:
the treatment improves one or more nasal polyposis-associated parameters selected from the group consisting of nasal congestion/obstructions (NC) severity, endoscopic NPS, computed tomography (CT) scan opacification of the sinuses, total symptoms score (TSS), sinonasal outcome test-22 (SNOT-22) score, loss of smell, runny nose, post nasal drip, and nasal peak inspiratory flow (NPIF);
the treatment decreases one or more of serum IgE levels, plasma eotaxin- 3 levels and serum thymus and activation-regulated chemokine (TARC) levels; and/or
the treatment decreases one or more of total IgE levels, eotaxin-3 levels, and eosinophil cationic protein (ECP) levels in nasal secretions of the subject.
19. A method for treating chronic rhinosinusitis with nasal polyposis (CRSwNP) in a subject in need thereof, wherein the subject has CRSwNP that is inadequately controlled by one or both of inhaled corticosteroid (ICS) and long-acting beta2 agonist (LABA) therapy, comprising:
administering to the subject a pharmaceutical composition comprising an antibody, or antigen binding fragment thereof, that specifically binds an interleukin-4 receptor (IL-4R), wherein the antibody, or antigen binding fragment thereof, comprises light chain CDR sequences of SEQ ID NOs: 6, 7 and 8, and heavy chain CDR sequences of SEQ ID NOs: 3, 4 and 5; and
administering to the subject one or more doses of intranasal corticosteroid (INCS).
20. The method of claim 19 , wherein the subject has a total of at least 5 nasal polyps, with two or more nasal polyps present in each nostril.
21. The method of claim 19 , wherein the subject has severe chronic rhinosinusitis with bilateral nasal polyposis.
22. The method of claim 19 , wherein the subject has co-morbid asthma.
23. The method of claim 19 , wherein the antibody, or antigen binding fragment thereof, is administered as an add-on maintenance treatment.
24. The method of claim 19 , wherein the subject further has one or more conditions selected from the group consisting of allergic rhinitis, asthma, aspirin hypersensitivity, and non-steroidal anti-inflammatory drug (NSAID) hypersensitivity.
25. The method of claim 19 , wherein:
the subject has undergone surgery for one or both of nasal polyps and chronic rhinosinusitis;
a first FESS is indicated, a revised surgery is indicated, or surgery is contraindicated; and/or
the antibody, or antigen binding fragment thereof, reduces a need for treatment with oral corticosteroids, systemic corticosteroids, and/or reduces a need for nasal polyp surgery.
26. The method of claim 19 , wherein the method:
decreases NPS by about 10% to about 50%, by about 20% to about 40%, or by about 25% to about 30%, and/or
improves one or more of loss of smell, runny nose, post nasal drip and nasal peak inspiratory flow, in the day (AM), at night (PM) or both in the AM and in the PM.
27. The method of claim 19 , wherein the antibody, or the antigen binding fragment thereof, is administered subcutaneously.
28. The method of claim 27 , wherein the antibody, or antigen binding fragment thereof, is administered using an autoinjector, a needle and syringe, or a pen delivery device.
29. The method of claim 19 , wherein the antibody, or the antigen binding fragment thereof, is administered in one or more doses of about 300 mg.
30. The method of claim 19 , wherein the antibody, or antigen binding fragment thereof, is administered in an initial dose of about 300 mg, and in one or more subsequent doses of about 300 mg each, and wherein the subsequent doses are administered once every 14 days.
31. The method of claim 19 , wherein the antibody, or antigen binding fragment thereof, comprises an HCVR having the amino acid sequence of SEQ ID NO:1 and an LCVR having the amino acid sequence of SEQ ID NO:2.
32. The method of claim 31 , wherein the antibody is dupilumab.
33. The method of claim 19 , wherein the method:
improves one or more nasal polyposis-associated parameters selected from the group consisting of nasal congestion/obstructions (NC) severity, endoscopic NPS, computed tomography (CT) scan opacification of the sinuses, total symptoms score (TSS), sinonasal outcome test-22 (SNOT-22) score, loss of smell, runny nose, post nasal drip, and nasal peak inspiratory flow (NPIF);
decreases one or more of serum IgE levels, plasma eotaxin- 3 levels and serum thymus and activation-regulated chemokine (TARC) levels; and/or
decreases one or more of total IgE levels, eotaxin-3 levels, and eosinophil cationic protein (ECP) levels in nasal secretions of the subject.
34. The method of claim 19 , wherein the INCS is mometasone furoate nasal spray (MFNS).
35. The method of claim 34 , wherein the MFNS is adminsitered at a dose of about 100 mg to each nostril of the subject once or twice a day.
36. A method for treating inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP) in a subject in need thereof, comprising administering to the subject an add-on maintenance treatment of a pharmaceutical composition comprising an antibody, or antigen binding fragment thereof, that specifically binds an interleukin-4 receptor (IL-4R), wherein the antibody, or antigen binding fragment thereof, comprises a heavy chain variable region (HCVR) having the amino acid sequence of SEQ ID NO: 1, and a light chain variable region (LCVR) having the amino acid sequence of SEQ ID NO: 2, and wherein the pharmaceutical composition is administered subcutaneously at a dose of about 300 mg every other week.
37. The method of claim 36 , wherein the antibody is dupilumab.
38. The method of claim 37 , wherein the dupilumab is administered subcutaneously.
39. The method of claim 38 , wherein the dupilumab is administered subcutaneously using an autoinjector, a needle and syringe, or a pen delivery device.